An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
T2 Biosystems, Inc. (NASDAQ:TTOO) announced the reporting of financial results for the first quarter of 2024 and business updates on May 6, 2024. The company specializes in rapid detection of sepsis-causing pathogens and antibiotic resistance genes.
T2 Biosystems, Inc. (NASDAQ:TTOO) ha annunciato la pubblicazione dei risultati finanziari per il primo trimestre del 2024 e aggiornamenti aziendali il 6 maggio 2024. L'azienda è specializzata nella rilevazione rapida di patogeni causanti la sepsi e geni di resistenza agli antibiotici.
T2 Biosystems, Inc. (NASDAQ:TTOO) anunció la presentación de resultados financieros para el primer trimestre de 2024 y actualizaciones de negocios el 6 de mayo de 2024. La compañía se especializa en la detección rápida de patógenos que causan sepsis y genes de resistencia a los antibióticos.
T2 Biosystems, Inc. (NASDAQ:TTOO)는 2024년 5월 6일에 2024년 첫 분기의 재무 결과와 비즈니스 업데이트를 발표했습니다. 이 회사는 패혈증을 유발하는 병원체와 항생제 저항성 유전자의 신속한 탐지를 전문으로 합니다.
T2 Biosystems, Inc. (NASDAQ:TTOO) a annoncé la publication des résultats financiers du premier trimestre 2024 et les mises à jour de l'entreprise le 6 mai 2024. L'entreprise est spécialisée dans la détection rapide des pathogènes provoquant la sepsis et des gènes de résistance aux antibiotiques.
T2 Biosystems, Inc. (NASDAQ:TTOO) gab am 6. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 sowie Geschäftsaktualisierungen bekannt. Das Unternehmen ist auf die schnelle Erkennung von Sepsis-verursachenden Pathogenen und Antibiotikaresistenz-Genen spezialisiert.
Positive
None.
Negative
None.
LEXINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2024 and business updates after market close on Monday, May 6, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International), passcode 160751, approximately ten to five minutes prior to the start time.
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2Biothreat™ Panel, and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the Candida auris test, and the T2Lyme™ Panel. For more information, please visit www.t2biosystems.com.
Investor Contact: Philip Trip Taylor, Gilmartin Group ir@T2Biosystems.com 415-937-5406
FAQ
When will T2 Biosystems report its first quarter 2024 financial results and business updates?
T2 Biosystems will report its first quarter 2024 financial results and business updates on May 6, 2024.
What is T2 Biosystems' ticker symbol?
T2 Biosystems' ticker symbol is TTOO.
Where can investors listen to the conference call about T2 Biosystems' financial results?
Investors can listen to the conference call about T2 Biosystems' financial results by accessing a live and archived webcast at www.t2biosystems.com or by dialing 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International) with passcode 160751.
t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www
